Shi Hanhan, Tian Hao, Zhu Tianyu, Liao Qili, Liu Chang, Yuan Peng, Li Yongyun, Yang Jie, Zong Chunyan, Jia Shichong, Ruan Jing, Ge Shengfang, Jia Renbing, Chai Peiwei, Xu Shiqiong, Fan Xianqun
Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
Cell Discov. 2024 Jun 11;10(1):63. doi: 10.1038/s41421-024-00683-y.
Conjunctival melanoma (CoM) is a potentially devastating tumor that can lead to distant metastasis. Despite various therapeutic strategies for distant metastatic CoM, the clinical outcomes remain unfavorable. Herein, we performed single-cell RNA sequencing (scRNA-seq) of 47,017 cells obtained from normal conjunctival samples (n = 3) and conjunctival melanomas (n = 7). Notably, we noticed a higher abundance of cancer-associated fibroblasts (CAFs) in tumor microenvironment (TME), correlated with enhanced angiogenic capacity and increased VEGFR expression in distal metastatic CoM. Additionally, we observed a significant decrease in the proportion of total CD8 T cells and an increase in the proportion of naive CD8 T cells, contributing to a relatively quiescent immunological environment in distal metastatic CoM. These findings were confirmed through the analyses of 70,303 single-cell transcriptomes of 7 individual CoM samples, as well as spatially resolved proteomes of an additional 10 samples of CoMs. Due to the increase of VEGFR-mediated angiogenesis and a less active T cell environment in distal metastatic CoMs, a clinical trial (ChiCTR2100045061) has been initiated to evaluate the efficacy of VEGFR blockade in combination with anti-PD1 therapy for patients with distant metastatic CoM, showing promising tumor-inhibitory effects. In conclusion, our study uncovered the landscape and heterogeneity of the TME during CoM tumorigenesis and progression, empowering clinical decisions in the management of distal metastatic CoM. To our knowledge, this is the initial exploration to translate scRNA-seq analysis to a clinical trial dealing with cancer, providing a novel concept by accommodating scRNA-seq data in cancer therapy.
结膜黑色素瘤(CoM)是一种具有潜在毁灭性的肿瘤,可导致远处转移。尽管针对远处转移性CoM有多种治疗策略,但临床结果仍然不理想。在此,我们对从正常结膜样本(n = 3)和结膜黑色素瘤(n = 7)中获得的47,017个细胞进行了单细胞RNA测序(scRNA-seq)。值得注意的是,我们发现肿瘤微环境(TME)中与癌症相关的成纤维细胞(CAF)丰度更高,这与远处转移性CoM中增强的血管生成能力和VEGFR表达增加相关。此外,我们观察到总CD8 T细胞比例显著下降,而幼稚CD8 T细胞比例增加,这导致远处转移性CoM中免疫环境相对静止。这些发现通过对7个个体CoM样本的70,303个单细胞转录组以及另外10个CoM样本的空间分辨蛋白质组的分析得到了证实。由于远处转移性CoM中VEGFR介导的血管生成增加以及T细胞环境活性较低,一项临床试验(ChiCTR2100045061)已启动,以评估VEGFR阻断联合抗PD1疗法对远处转移性CoM患者的疗效,显示出有前景 的肿瘤抑制作用。总之,我们的研究揭示了CoM肿瘤发生和进展过程中TME的格局和异质性,为远处转移性CoM的管理提供了临床决策依据。据我们所知,这是将scRNA-seq分析转化为癌症临床试验的初步探索,通过在癌症治疗中纳入scRNA-seq数据提供了一个新概念。